BRTX
BioRestorative Therapies, Inc.Company Information
- Company Name
- BioRestorative Therapies, Inc.
- CIK
- CIK0001505497
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BRTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 8090
- SIC Description
- Services-Misc Health & Allied Services, NEC
- Ticker
- BRTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-04-09
- Last sale
- 2024-10-28
- Shares purchased (TTM)
- 129,015
- Shares sold (TTM)
- 1,640
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,955,389
- Shares outstanding
- 17,727,747
- Ownership
- 11.03%
Earnings Market Reaction
- Filing date
- 2026-05-14
- Price on filing date
- —
- 1-month reaction
- 114.40%
- 3-month reaction
- 8.36%
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 3 | 2 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | ||||||
| Marketable Securities Current | 0 | 1 | 4 | 6 | 8 | 10 | 12 | 12 | 15 | 10 | 10 | 10 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Offering Costs | - | - | - | - | - | - | 0 | - | - | - | - | - | ||||||
| Assets Current | 4 | 3 | 5 | 8 | 9 | 11 | 14 | 15 | 17 | 11 | 13 | 12 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Deferred Costs | - | - | - | - | - | - | - | 0 | 0 | - | - | - | ||||||
| Assets | 5 | 4 | 6 | 9 | 10 | 12 | 15 | 16 | 18 | 13 | 14 | 13 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Accrued Liabilities Current | 1 | 1 | 1 | 0 | 0 | 1 | - | - | - | - | - | - | ||||||
| Accrued Liabilities Current | - | - | - | - | - | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||||||
| Deferred Revenue | - | - | - | - | - | - | - | 0 | - | - | - | - | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Current | - | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 3 | 2 | - | - | ||||||
| Contract With Customer Liability Current | - | - | - | - | 0 | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 2 | 4 | 3 | 4 | 4 | 4 | 5 | 5 | 3 | 3 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities | - | - | - | 4 | 4 | 4 | 5 | 5 | 3 | 3 | 1 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | 0 | 0 | 0 | - | 0 | 0 | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 175 | 170 | 169 | 169 | 167 | 164 | 164 | 164 | 163 | 157 | 177 | 174 | ||||||
| Retained Earnings Accumulated Deficit | -172 | -170 | -167 | -164 | -161 | -156 | -154 | -153 | -149 | -147 | -164 | -161 | ||||||
| Stockholders Equity | 3 | 0 | 2 | 5 | 6 | 9 | 10 | 11 | 15 | 10 | 11 | 3 | ||||||
| Liabilities And Stockholders Equity | 5 | 4 | 6 | 9 | 10 | 12 | 15 | 16 | 18 | 13 | 14 | 13 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | ||||||
| Common Stock Shares Issued | 25 | 9 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 5 | 5 | 4 | ||||||
| Shares Outstanding | 25 | 9 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 5 | 5 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBioRestorative Therapies, Inc. (BRTX) — SEC Financial Statements & Analysis
BioRestorative Therapies, Inc. (BRTX) is a services-misc health & allied services, nec company, incorporated in NV. BioRestorative Therapies, Inc. trades on Nasdaq as: BRTX. BioRestorative Therapies, Inc. (BRTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-14. Based on that filing, BioRestorative Therapies, Inc. carries a market cap of $4.82M, a P/E ratio of -0.44x, a P/B ratio of 1.59x, a P/S ratio of 13.48x, an enterprise value of $1.71M, and an EV/EBITDA multiple of -0.12x. On profitability, it posts a gross margin of 92.09%, an operating margin of -3975.00%, a net margin of -3089.55%, a Return on Equity (ROE) of -241.14%, a Return on Assets (ROA) of -147.75%, and a Return on Invested Capital (ROIC) of -286.74%. Per share, it reports EPS of $-0.62, diluted EPS of $-0.62, free cash flow per share of $-0.67, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -8.47% year-over-year, net income growth of -8.59% year-over-year, and EPS growth of -56.91% year-over-year. On the balance sheet, it maintains a current ratio of 2.35x, a quick ratio of 2.23x, working capital of $2.19M, a debt-to-equity ratio of 0.53x, a debt ratio of 0.35, an interest coverage ratio of -85.57x, free cash flow of $-11.90M (TTM), and net debt of $-3.11M. Figures sourced from SEC EDGAR.
- Market Cap
- $4.82M
- P/E TTM
- -0.44x
- EPS TTM
- $-0.62
- P/B TTM
- 1.59x
- ROE TTM
- -241.14%
- ROA TTM
- -147.75%
- Debt To Equity
- 0.53x
- Free Cash Flow TTM
- $-11.90M
- Net Revenue TTM Growth 1Y
- -8.47%
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BioRestorative Therapies, Inc. in?
BioRestorative Therapies, Inc. (BRTX) operates in the Services-Misc Health & Allied Services, NEC industry.
What exchange does BRTX trade on?
BioRestorative Therapies, Inc. (BRTX) trades on the Nasdaq.
Where is BioRestorative Therapies, Inc. incorporated?
BioRestorative Therapies, Inc. is incorporated in NV.
When was BioRestorative Therapies, Inc. (BRTX)'s most recent SEC filing?
BioRestorative Therapies, Inc. (BRTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-14.
What is BRTX's market cap?
BioRestorative Therapies, Inc. (BRTX) has a market capitalization of $4.82M as of 2026-03-31.
What is BRTX's EPS (earnings per share)?
BioRestorative Therapies, Inc. (BRTX)'s trailing twelve month EPS is $-0.62 as of 2026-03-31.
What is BRTX's ROE (return on equity)?
BioRestorative Therapies, Inc. (BRTX)'s trailing twelve month Return on Equity (ROE) is -241.14% as of 2026-03-31.
What is BRTX's ROA (return on assets)?
BioRestorative Therapies, Inc. (BRTX)'s trailing twelve month Return on Assets (ROA) is -147.75% as of 2026-03-31.
What is BRTX's ROIC (return on invested capital)?
BioRestorative Therapies, Inc. (BRTX)'s trailing twelve month Return on Invested Capital (ROIC) is -286.74% as of 2025-09-30.
What is BRTX's EV/EBITDA?
BioRestorative Therapies, Inc. (BRTX)'s trailing twelve month EV/EBITDA is -0.12x as of 2026-03-31.